TransMedics Group, Inc. (TMDX)
Nasdaq · Healthcare · Medical Devices
$82.99+4.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.9B
- P/E (trailing)
- 21.5
- Forward P/E
- 36.7
- 52-week range
- $60.11 – $156.00
- 52-week change
- −30.72%
- EPS (trailing)
- $3.86
- Analyst rating
- 1.8 Buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $605M (+37.13%)
- Net income
- $190M
- Operating margin
- 17.9%
- Diluted EPS
- $4.87
- Free cash flow
- $134M
From the company’s annual report on SEC EDGAR.
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Headquarters: Andover, United States · 898 employees · transmedics.com